Alveo Technologies Curates economically viable disease diagnostic devices

On having received $ 38 million Series A financing by Maxim Merchant Capital, Alveo technologies to embark on curation of efficient and cost-effective disease diagnostic devices aiding the commercialization of Alveo’s rapid diagnostic platform for infectious diseases.

Ron Chiarello Ph.D., Founder and Chief Executive Officer of Alveo proclaimed “We are pleased to have attracted a strong syndicate of investors to Alveo. This funding accelerates our vision to provide lifesaving medical information to those who need it, at the most critical times — with technology that is flexible, inexpensive, and accessible worldwide”. He insisted that “Our team is focused on delivering the global health benefits that are now within reach.”